Beam Therapeutics BEAM and Intellia Therapeutics NTLA are clinical-stage companies developing investigational gene therapies.

CRISPR Therapeutics is the subject of strong buyout speculation after earning FDA approval for a breakthrough gene-editing ...

Taysha Gene Therapies Inc. (NASDAQ: TSHA) is a must-buy penny stock to buy now. On November 13, Piper Sandler analyst Biren ...

While shares of Regeneron Pharmaceuticals are climbing this month, investors shouldn't find the stock too pricey, as it's ...

Also Read: Vinay Prasad’s Appointment To FDA’s CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation Additionally, the company revealed clinical data from Part A of the REVEAL Phase ...

Genetic manipulation – or gene editing – is a concept that describes altering the genetic material (DNA) of an organism.

Discoveries made by companies in the genetics sector help support every other life science industry in a variety of ways. One of the genetic sector's major contributions is the discovery of new ...

Taysha Gene Therapies, Inc. announced the granting of stock options to two new employees, totaling 401,000 shares of common stock, as part of their employment package. These options were granted under ...

Genetic Technologies (NASDAQ:GENE) stock tumbled 26% in afternoon trading Thursday after the genomics-based test developer announced a $2M registered direct offering. Shares of Genetic Technologies ...

Now, it’s worth noting Stock Advisor’s total average return is 1,002% — a market-crushing outperformance compared to 190 % ...